Effect of astaxanthin on cataract formation induced by glucocorticoids in the chick embryo. 2015

Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
Department of Ophthalmology, School of Medicine, Iwate Medical University , Morioka , Japan and.

OBJECTIVE To examine whether astaxanthin (AST) prevent the cataract formation induced by glucocorticoid in chick embryo. METHODS Hydrocortisone hemisuccinate sodium (HC) (0.5 μmol/egg) was administered directly into the air chamber in the egg shell of chick embryo day 15. The eggs were then kept in an incubator at same conditions and administered 100 μL of 50 (HC + AST50 group), 80 (HC + AST80 group), 100 (HC + AST100 group) mg/mL of AST solutions dissolved in dimethyl sulfoxide (DMSO) 3 h after administration of HC. In addition, non-HC treated group (treated with physiological saline without HC and 100 μL of DMSO), HC-alone group (treated with 0.5 μmol of HC and 100 μL of DMSO), and AST100 group (treated with physiological saline without HC and 100 μL of DMSO) were also incorporated. After 48 h of treatment, lenses were removed from embryo and classified into five stages according to developed opacity. The amounts of reduced glutathione in the lenses and the blood glucose levels were measured. RESULTS The average scores of lens opacitiy were 2.63 ± 1.02 nmol/lens (HC-alone), 2.78 ± 0.97 nmol/lens (HC + AST50), 2.22 ± 1.20 nmol/lens (HC + AST80) and 1.84 ± 0.83 nmol/lens (HC + AST100; p < 0.05), respectively. Administration of AST decreased the lens opacity dose-dependently. The amounts of reduced glutathione in lenses were 11.6 ± 2.8 nmol/lens (HC-alone), 11.3 ± 2.7 nmol/lens (HC + AST50), 13.4 ± 2.4 nmol/lens (HC + AST80) and 13.7 ± 3.1 nmol/lens (HC + AST100; p < 0.05), respectively. Higher levels of AST prevented loss of reduced glutathione from the lens. CONCLUSIONS These findings support that AST protects glucocorticoid-induced cataract in chick embryo.

UI MeSH Term Description Entries
D007908 Lens, Crystalline A transparent, biconvex structure of the EYE, enclosed in a capsule and situated behind the IRIS and in front of the vitreous humor (VITREOUS BODY). It is slightly overlapped at its margin by the ciliary processes. Adaptation by the CILIARY BODY is crucial for OCULAR ACCOMMODATION. Eye Lens,Lens, Eye,Crystalline Lens
D002386 Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed) Cataract, Membranous,Lens Opacities,Pseudoaphakia,Cataracts,Cataracts, Membranous,Lens Opacity,Membranous Cataract,Membranous Cataracts,Opacities, Lens,Opacity, Lens,Pseudoaphakias
D002642 Chick Embryo The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching. Embryo, Chick,Chick Embryos,Embryos, Chick
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D018384 Oxidative Stress A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi). Anti-oxidative Stress,Antioxidative Stress,DNA Oxidative Damage,Nitro-Oxidative Stress,Oxidative Cleavage,Oxidative DNA Damage,Oxidative Damage,Oxidative Injury,Oxidative Nitrative Stress,Oxidative Stress Injury,Oxidative and Nitrosative Stress,Stress, Oxidative,Anti oxidative Stress,Anti-oxidative Stresses,Antioxidative Stresses,Cleavage, Oxidative,DNA Damage, Oxidative,DNA Oxidative Damages,Damage, DNA Oxidative,Damage, Oxidative,Damage, Oxidative DNA,Injury, Oxidative,Injury, Oxidative Stress,Nitrative Stress, Oxidative,Nitro Oxidative Stress,Nitro-Oxidative Stresses,Oxidative Cleavages,Oxidative DNA Damages,Oxidative Damage, DNA,Oxidative Damages,Oxidative Injuries,Oxidative Nitrative Stresses,Oxidative Stress Injuries,Oxidative Stresses,Stress Injury, Oxidative,Stress, Anti-oxidative,Stress, Antioxidative,Stress, Nitro-Oxidative,Stress, Oxidative Nitrative,Stresses, Nitro-Oxidative
D024341 Xanthophylls Oxygenated forms of carotenoids. They are usually derived from alpha and beta carotene. Xanthophyll Carotenoids,Carotenoids, Xanthophyll

Related Publications

Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
September 1984, Investigative ophthalmology & visual science,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
July 1991, Current eye research,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
June 1994, Experimental eye research,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
October 2019, The Indian journal of medical research,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
April 1983, Experimental eye research,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
January 1989, Investigative ophthalmology & visual science,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
July 1994, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
January 1963, Nature,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
January 1995, Ophthalmic research,
Sayano Ishikawa, and Kouhei Hashizume, and Hideo Nishigori, and Yu Tezuka, and Atsushi Sanbe, and Daijiro Kurosaka
August 1984, Life sciences,
Copied contents to your clipboard!